NCT03736993 (PROLUNG) is a NA clinical trial of Additional blood sampling in NSCLC, Stage IIIA, sponsored by Hasselt University.

Who is sponsoring NCT03736993?

NCT03736993 is sponsored by Hasselt University.

What drugs are being tested in NCT03736993?

Interventions in NCT03736993: Additional blood sampling.

What condition does NCT03736993 study?

NCT03736993 studies NSCLC, Stage IIIA.

Is NCT03736993 still recruiting?

NCT03736993 is currently completed. Last updated 15 December 2023.

Last reviewed 2023-12-15 · How we verify

NCT03736993: PROLUNG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolomics Predict Therapy Response

Completed NA Last updated 15 December 2023

What this trial tests

NA trial testing Additional blood sampling in NSCLC, Stage IIIA in 160 participants. Completed in 31 December 2022.

Timeline

28 May 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Hasselt University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	160
Start date	28 May 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	4 locations across Belgium

Drugs / interventions tested

Additional blood sampling — full drug profile →

Conditions studied

NSCLC, Stage IIIA — all drugs for NSCLC, Stage IIIA →

Sponsor

Hasselt University

Who can join

18 and older, any sex, with NSCLC, Stage IIIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Complete resection is the mainstay of treatment for stage I-IIIA resectable non-small cell lung cancer (NSCLC). However rates of recurrence of disease are high, with five-year survival rates ranging between 73% (stage IA) and 24% (stage IIIA). Therefore, a prognostic biological marker that stratifies between NSCLC patients whom surgery cures versus patients in whom surgery would be futile due to early disease relapse after surgery is eagerly awaited. The primary objective of this prospective study is to establish a prognostic marker of early disease progression after complete surgical resection in patients with stages I to IIIA NSCLC. For this purpose the investigator will compare the metabolic profile with disease progression or death within one year after complete surgical resection to the patients with a progression free survival. Furthermore the investigator will evaluate the changes in the metabolic profile after surgery and if changes in this metabolic profile over time can predict disease recurrence before it becomes clinically apparent.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

NMR-Metabolomics Reveals a Metabolic Shift after Surgical Resection of Non-Small Cell Lung Cancer.
Derveaux E, Geubbelmans M, Criel M, Demedts I, et al · · 2023 · cited 5× · PMID 37046788 · DOI 10.3390/cancers15072127
Plasma Metabolite Profiling in the Search for Early-Stage Biomarkers for Lung Cancer: Some Important Breakthroughs.
Meynen J, Adriaensens P, Criel M, Louis E, et al · · 2024 · cited 2× · PMID 38731909 · DOI 10.3390/ijms25094690

Verify or expand the search:

Other trials of Additional blood sampling

Trials testing the same drug.

NCT06057844 — Molecular Imaging of Active Venous Thrombus With Positron Emission Tomography (PET) · NA · unknown
NCT04393701 — A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry · NA · recruiting

Other recruiting trials for NSCLC, Stage IIIA

Currently open trials in the same condition.

NCT04865250 — Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC · Phase 2 · recruiting

Other Hasselt University trials

Trials by the same sponsor.

NCT07419100 — Sedentary Behaviour, Physical Activity Patterns, and Cardiometabolic Health · NA · not yet recruiting
NCT07505355 — Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis · recruiting
NCT07081893 — How do Patients, Relatives and Healthcare Professionals View Person-centered Rehabilitation. · not yet recruiting
NCT06785909 — Proprioceptive, Fear-related and Inflammatory Factors in the Persistence of Pregnancy-related Lumbopelvic Pain. · NA · recruiting
NCT07175792 — Accuracy of Motor Performance Perception in Multiple Sclerosis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03736993 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hasselt University
Last refreshed: 15 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03736993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing